Q & A Library
Does New Prostate Cancer Drug Really Work?
What are your thoughts and opinions on a drug called MDV3100 for prostate cancer elimination in advanced-stage patients?
Answer (Published 10/29/2009)
MDV3100 is an experimental drug that appears to hold great promise for treatment of advanced prostate cancer that resists current drugs. The majority of today’s drugs block androgens, the male sex hormones that foster the cancer’s growth and spread. Treatment results in "chemical castration." Advanced, resistant disease is called "castration-resistant prostate cancer" or CRPC.
MDV3100 has been studied in cell cultures, where it worked well, and in mice, where it shrank tumors, but so far, it has been studied in only two human trials. The first enrolled 30 men with advanced CRPC. In 22 of the men, levels of prostate-specific antigen (PSA), a marker for tumor growth, declined with MDV3100 treatment. In 13 of those cases PSA levels fell by more than half. A second trial with 110 men tested higher doses, which reportedly were well tolerated. The company that produces MDV3100 announced in March, 2009, that it has FDA permission to launch a randomized, placebo-controlled, double-blind, multinational trial to assess overall survival with MDV3100. A total of 1,200 men with advanced CRPC will be enrolled.
If all goes well, it will be at least three to four years before MDV3100 could be ready for FDA evaluation and even longer before it becomes available for treatment.
If you’re looking for ways to lower your risk of prostate cancer, here’s what I recommend:
Andrew Weil, M.D.
Some Rights Reserved Creative Commons Copyright Notice
A portion of the original material created by Weil Lifestyle on DrWeil.com (specifically, all question and answer-type articles in the Dr. Weil Q&A Library) is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.